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Nitric oxide synthase induction with renal transplant rejection or
infection
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Nitric oxide synthase induction with renal transplant rejection or
infection. Nitric oxide (NO) is readily oxidized to nitrate and nitrite and
NO activates guanylyl cyclase, increasing cyclic GMP levels. To determine
if nitric oxide synthase (NOS) is present in urine collected daily from
patients following renal transplantation, we evaluated NOS activity in the
leukocyte-rich particulate fraction and measured nitrate, nitrite, and cyclic
GMP levels in the supernatant fraction of the urine. Reverse transcrip-
tase-PCR and eDNA sequencing confirmed the presence of inducible
NOS (iNOS) in cells obtained from the urine of renal transplant patients
with rejection. NOS activity was elevated significantly in renal transplant
patients with rejection (6.40 1.47 pmol citrulline/min/mg protein) or
with urinary tract infection (29.56 11.00 pmol citrulline/min/mg pro-
tein), when compared to post-renal transplantation patients without
rejection or urinary tract infection (0.51 0.21 pmol citrulline/min/mg
protein). Nitrate levels increased in renal transplant patients with rejec-
tion and nitrite levels increased in renal transplant patients with urinary
tract infection (UTI). Cyclic GMP levels increased with both rejection and
UTI. This study demonstrates the presence of NOS activity and inducible
NOS-mRNA in cells isolated from the urine of patients undergoing renal
allograft rejection.
Cytokines and endotoxins induce nitric oxide synthase (NOS)
which increases biologically-active nitric oxide (NO) that is readily
oxidized to nitrate and nitrite [1, 2]. Nitric oxide is a ubiquitous
messenger molecule that can exert pro-inflammatory, bacterio-
cidal, and anti-viral actions [1—3]. We identified inducible NOS
(iNOS) in human urinary leukocytes [4—61 from patients with
bacterial urinary tract infections (UTI). When iNOS activity is
elevated in the urine of patients with UTI, guanylyl cyclase is
activated and cyclic GMP (cGMP) levels increase [71.
Cytokines participating in the immune response to alloantigens
also induce NOS [8—10]. With cardiac, renal, and islet transplan-
tation in rats, iNOS expression and elevated nitrite and nitrate
levels are associated with allograft rejection [8, 1 1—15J. In human
liver transplant patients, plasma nitrate [16] and plasma nitroso-
compound levels [17] are increased with acute liver rejection.
After allogeneic bone marrow transplantation in humans, there is
a significant rise of serum nitrate and nitrite levels preceding the
onset of clinical symptoms of graft-versus-host disease [18].
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Although elevated levels of nitrate and nitrite have been
demonstrated with human liver [16, 17] and bone marrow trans-
plantation rejection [18], there have been no studies demonstrat-
ing elevation of nitric oxide by-products with renal transplant
rejection nor studies showing activation of iNOS in cells isolated
directly from patients with any form of allograft transplant
rejection. The purpose of the present study is to examine the
changes in NOS activity and NOS-mRNA expression in urinary
cells isolated from renal transplant patients with rejection or
infection. Following the time course of NOS activity in renal
transplantation patients, we find an acute increase in NOS
activity, not only its by-products, occurring prior to the clinical
diagnosis of rejection and a significant rise of NOS activity when
renal transplantation is accompanied by a UTI.
Methods
Patient population
A total of 25 renal transplant recipients at the Yale-New Haven
Hospital were evaluated. The average age of the patients (13
males and 12 females) was 45.1 2.5 years (range 19 to 68 years).
Eleven patients had cadaveric renal transplantations and 14 had
living-related transplantations. Ten transplant recipients had an
episode of acute renal graft rejection (defined by a rising serum
creatinine and confirming histopathology as determined by allo-
graft biopsy) that responded to pulse corticosteroids or to OKT3.
All primary urinary samples obtained from patients diagnosed
with acute transplant rejection had at least 3 white blood cells!
high power field and 90% of the patients had more than 3 white
blood cells/high power field. Eight of the transplant recipients
were diagnosed to have UTIs (UTI is defined as significant
urinary bacteriuria, greater than 100,000 CFU/ml of a predomi-
nating microorganism). Of the patients with complications after
renal transplantation, one patient was diagnosed with an intestinal
perforation and transplant rejection and one was diagnosed with
a urine leak and a UTI.
Urine sample isolation
Urine samples were collected from the following groups of
hospitalized patients: (1) patients with chronic renal failure who
had not undergone renal transplantation; (2) post-renal trans-
plant patients without infection or rejection and with decreasing
or stable serum creatinine (Cr) levels (controls); (3) renal trans-
plant patients with UTIs; and (4) renal transplant patients with
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acute, clinically significant transplant rejection. If rejection and
infection occured together, the patient's values were included with
renal transplant patients with UTIs. Urine samples were obtained
daily during the first hospitalization of the transplant patient and
subsequently if the transplant patient developed fever, abdominal
pain, or rising serum Cr levels. Urine samples were "clean-catch"
specimens (23%) or sterile catheterization specimens (77%).
Each urine sample was stored on ice and centrifuged (1700 )< g
for 5 mm, 4°C). Urine supernatant was isolated and stored at
—80°C until analysis for nitrite, nitrate and eGMP levels. The
leukocyte-rich urine sediment was processed for NOS activity and
for RNA isolation.
Assay of NOS activity
The urine pellet was resuspended in ice cold PBS and centri-
fuged 1700 X g for five minutes [4—7]. The resultant pellet was
resuspended in homogenization buffer [4°C, 20 mM Hepes, pH
7.4, 1.0 mvt DTT, 0.05 m'vi PMSF, leupeptin (0.2 mgIlOO ml) and
1.0 mg/i00 ml each of soybean trypsin inhibitor, pepstatin,
antipain, and chymostatin] and homogenized (10 seconds, at 70%
power) using an Ultra/Turrax, T25 (IKA, Cincinnati, OH, USA).
The particulate fraction of the urine pellet was washed three times
with homogenization buffer and stored at —80°C until analysis.
Previously, we have shown that 90% of the human iNOS activity
is found in the urinary particulate fraction [4].
NOS activity was measured as the formation of ['4C]-L-citrul-
line from ['4C]-L-arginine (340 mCi/mmol; DuPont/NEN, Wil-
mington, DE, USA). The particulate enzyme or buffer control was
incubated (37°C, 45 mm) with ['4C]-L-arginine (0.2 j.tCi, 3 j.trvi) in
homogenization buffer containing 2.0 m'vi valine, 2.0 mi NADPH,
and 1.0 mrvi CaC12. The NOS inhibitor, N°-monomethyl-L-argi-
nine (L-NMMA), when used, was added immediately prior to
incubation. L-NMMA, NADPH, and all protease inhibitors were
obtained from Sigma Chemical Company (St. Louis, MO, USA).
The assay was terminated with 1.0 ml of 20 mrvi Hepes (pH 5.5)
containing 2.0 mrt EDTA. The sample was then applied to a 1.0
ml column of AG 50W-X8, Na form (Bio-Rad, Hercules, CA,
USA) and eluted with 1.0 ml of Hepes (pH 5.5). The column
effluent was measured in a liquid scintillation counter, after
addition of 15 ml of Optifluor (Packard, Meriden, CT, USA).
Thin layer chromatography of the AG 50W-X8 column effluent
from the NOS activity assay showed that 88% of the radioactivity
migrated as citrulline [4]. [14C]-L-citrulline formation in the
presence of L-NMMA is subtracted from total ['4C]-L-citrulline
product, so that all data are expressed in terms of L-NMMA
inhibitable activity. After hydrolyzed with NaOH, protein concen-
trations were measured using the Bradford method [191 with
bovine gamma-globulin as a standard (Bio-Rad, Hercules, CA,
USA).
For determining NOS activity in renal transplant patients who
developed rejection or infection, the significantly elevated NOS
values, measured daily < three days prior to the clinical diagnosis
of rejection or infection and with treatment during the patient's
first hospitalization, were averaged for each patient. The NOS
values for patients who returned for hospitalization with rejection
or infection were measured daily and averaged for each patient.
Although urine was collected daily during the patients' hospital-
ization, on some days there was insufficient particulate fraction for
NOS analysis. The patients' average NOS activity values were
summed and averaged for each disease process. Control NOS
activity values were obtained from renal transplant patients who
developed neither rejection nor infection during the first hospi-
talization. Control values were obtained daily following transplan-
tation and were averaged.
Nitrite and nitrate levels
To determine endogenous urinary nitrite levels [4], Griess
reagent (100 p1) was added to urine (100 p1) or to sodium nitrite
standards (2.9 to 58 !.tM) and incubated for 15 minutes. Nitrite was
measured spectrophotometrically at 546 nm. Urinary nitrate
levels were measured after reduction of nitrate to nitrite with
bacterial nitrate reduetase. Nitrate standards (ito 40 1.tM) or 1:20
dilutions of urine supernatant were incubated (30 mm, 37°C) with
0.25 U/ml nitrate reductase (Sigma N7265, from Aspergillus), 250
j.tM NADPH, and 20 /kM flavin adenine dinucleotide in PBS [20].
To oxidize NADPH, 10 mM pyruvate and 10 U lactate dehydro-
genase (Sigma L2500 from rabbit muscle) were added [211, the
mixture was incubated for an additional 10 minutes (37°C), and
the nitrite concentration was determined. Nitrate was linear over
this concentration and there was a 100% conversion of nitrate to
nitrite. Since this assay measures both nitrite derived from the
reduction of nitrate and endogenous nitrite, endogenous nitrite
levels were subtracted to determine nitrate levels.
Urine creatinine (Cr) levels were measured spectrophotometri-
cally, using the alkaline picrate method (Sigma) [22]. Results are
reported as both /kmol/liter urine and as imol/g Cr.
Cyclic GMP levels
Cyclic GMP levels were determined in 1:50 or 1:100 dilutions of
urine supernatants using an ['251]-radioimmunoassay (Biomedical
Technologies, Stoughton, MA, USA). Results are reported as
jimol cGMP/g ereatinine.
RT-PCR
RNA was isolated from urinary pellets of transplant patients
with infection and rejection using the Trizol reagent (Life Tech-
nologies, Inc., Gaithersburg, MD, USA). Single stranded eDNA
was synthesized with oligo dT priming and Superscript Il-Reverse
transeriptase (Gibco BRL, Life Technologies, Gaithersburg, MD,
USA). Previous Southern blots of neutrophil-PCR products from
patients with urinary tract infections detected iNOS and endothe-
hal NOS (eNOS), but not neuronal NOS (bNOS) [61. Human
iNOS specific primers did not amplify the other forms of NOS [6].
For this study, two sets of iNOS specific primers, (5'-CACCTT-
TGATGAGGGGAC-3', sense) and (5'-GCATCCAGCTTGAC-
CAG-3', antisense) and iNOS sense and antisense primers de-
scribed by Reiling et al [23], allowed amplification of the desired
eDNA. /3-actin specific primers were used as control.
Statistical analysis
Results are expressed as mean SEM. N = the patients
evaluated and n = the samples evaluated. Means are compared
using the Student's t-test. Significance level is 95% for all analyses
(P < 0.05).
Results
NOS activity with acute transplant rejection or with infection
Prior to transplantation, NOS activity in urinary pellets from
both male and female patients with chronic renal failure was
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Fig. 1. Urine particulate NOS activity for transplant controls, renal trans-
plant patients with rejection, and renal transplant patients with infection.
NOS values for patients with transplant rejection or infection are averaged
and compared to average NOS values from control patients. Significant
differences between all groups are greater than 95% by the Student's
t-test.
0.56 0.20 pmol citrulline/min/mg protein (N = 5; Figs. I and 2).
Similarly, urinary NOS activity, measured daily after transplanta-
tion in non-rejecting, non-infected renal transplant recipients
(control patients), was 0.51 0.21 pmol citrulline/min/mg protein
(N = 6; 1 to 6 samples were evaluated from each patient). During
acute renal transplant rejection, urinary NOS activity was 6.40
1.47 pmol citrulline!min/mg protein (N = 10; ito 4 samples were
evaluated from each patient). In hospitalized patients, this in-
crease in NOS activity was demonstrated 1.8 0.3 days prior to
the clinical diagnosis of rejection (N = 6). Two patients were
discharged with elevated NOS activity and subsequently returned
for hospitalization with acute renal transplant rejection.
NOS activity increased to a significantly greater extent in
association with bacterial UTIs than with transplant rejection.
With UTIs, NOS activity increased to 29.56 11.00 pmol
citrulline/min/mg protein (N = 8; 1 to 3 samples were evaluated
from each patient). With renal transplant rejection and infection,
NOS activity remained elevated while the patient was hospital-
ized. With patient follow-up after hospitalization, the NOS values
decreased to 0.18 + 0.07 pmol citrulline/min/mg protein (N = 6).
Post-operative day
Fig. 2. Urine particulate NOS activity as a function of the post-operative day
following renal transplantation. In a representative patient who develops
rejection (LI) and in a representative patient who develops a UTI (A), the
time of clinical diagnosis of the disease is noted with an arrow. Although
urine was collected daily during the initial hospitalization following
transplantation, on some days there was insufficient particulate fraction
for NOS analysis.
Nitrate and nitrite excretion differs with transplant rejection
and infection
Among patients with normal post-transplant renal function,
urinary nitrate levels were 1110 142 mol/liter (n = 32) and
urinary nitrite levels were 11.5 1.3 j.mol/liter (n = 32). With
rejection prior to treatment, nitrate levels were significantly
increased [4350 708 .tmol/1iter (N = 10)1, but nitrite levels did
not change [9.2 1.4 mol/liter (N = 10)1. In contrast, with the
onset of infection, nitrite levels were significantly increased
[99.4 48.3 .tmol/liter (N = 8)1 while nitrate values did not
change significantly [850.3 100.8 .rmol/liter (N = 8)1 (Fig. 3).
When nitrite levels were normalized using urinary Cr levels
(Table 1), patients with normal post-renal transplant function had
levels of 19.9 2.5 mol/g Cr, patients with transplant rejection
had levels of 22.4 3.6 imol/g Cr, and patients with infection had
levels of 163 35.8 mol/g Cr. When nitrate levels were
normalized using urinary Cr, nitrate levels were elevated in
patients with rejection when compared to control transplant
patients and transplant patients with infection, 4937 763 mol/g
Cr, 1585 296 mol/g Cr, and 1900 510 itmol/g Cr, respec-
tively.
Cyclic GMP levels were increased with transplant rejection
and infection
The average urinary cGMP level in control patients, individuals
with good renal function, after transplantation was 0.66 0.03
.tmol cGMP/g Cr (range 0.29 to 1.2 tmol cGMP/g Cr; N = 54).
Cyclic GMP levels rose to 2.0 0.17 gmol cGMP/g Cr (range 1.2
to 3.1 .rmol cGMP/g Cr; N = 10) with rejection and to 2.5 0.36
jimol cGMP/g Cr (range 1.2 to 4.0 imol cGMP/g Cr; N = 8) with
infection. We observed no significant difference in cGMP levels
between transplant patients with infection or rejection. Figure 4
shows average cGMP values from seven renal transplantation
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Nitrite
Fig. 3. Nitrate and nitrite concentrations with transplant rejection and
infection. Compared to transplant control patients (LI), nitrite (mol/liter)
is significantly elevated in urine from transplant patients with urinary
infection (U) and nitrate Qmol/liter) is significantly elevated in urine from
transplant patients with rejection (). *Thc significant differences are
greater than 95% (Student's t-test).
patients before and after developing an infection (N = 3) or
rejection (N = 4).
iNOS gene expression in renal transplant patients with infection
or rejection
RNA isolated from urine pellet of patients with infection or
transplant rejection was used for RT-PCR. Using two different
sets of iNOS specific primers, 413 bp and 462 bp fragments were
amplified (Fig. 5). Both primer sets amplified the human hepato-
cyte iNOS-cDNA but not human endothelial NOS-cDNA. DNA
sequencing of both products revealed greater than 99% sequence
identity to human hepatocyte iNOS.
Discussion
This study demonstrates that renal transplant rejection and
infection increase human iNOS activity in the leukocyte-enriched
pellet obtained from the urine of transplant patients. The increase
in NOS activity occurs despite differences in the source of the
transplanted kidney, cadaveric or living-related donor transplan-
tation, or in the patient's dietary intake or administered medica-
tions. Most importantly, the increase in NOS activity occurs prior
to the clinical diagnosis of rejection.
While NOS activity is elevated in the urine particulate fraction
from renal transplant patients with rejection, the NOS activity is
even higher in transplant patients with bacterial UTI. Previously,
in bacterial infected urine from patients, iNOS was demonstrated
by Western blot analysis, RT-PCR and sequencing, and immuno-
histochemistry of neutrophils which verified that the elevated
['4Cj-L-citrulline formation is due to iNOS activity [5, 6].
Reasons for the differences in the magnitude of NOS activity
with rejection and infection in renal transplant patients include
differences in the cell populations found in the urine with the two
different disease states and the presence of bacterial products,
such as lipopolysaccharides, known inducers of NOS in the urine
of patients with UTIs [5, 6]. Urine cytologic monitoring per-
formed after pancreas-kidney and kidney transplantation reveals
Control Rejection Infection
NOS activity 0.53 0.12 6.40 l.47'' 29.6 1100ah
pmol citrulline!minlmg n 19 N = 10 N = 8
protein
Nitrate level 1585 296 4937 763' 1900 510
p.mol/gCr n=32 N=10 N=8
Nitrite level 19.9 2.5 22.4 3.6 163 35.8'
unol/gCr n=32 N10 N=8
Cyclic GMP level 0.66 0.03 2.0 0.1T 2.5 0.36'
pmol/gCr n=54 N=10 N=8
NOS activity reported is described in the Methods section. The values
reported for nitrate, nitrite and cGMP levels are the peak levels measured
during transplant rejection or infection. For all experiments, the control
levels are from patients with a stable recovery after transplantation. N =
patients evaluated and n = samples evaluated.
a Significant difference between control and rejection or infection is >
95%
b Significant difference between rejection and infection is > 95%
lymphocyturia with both acute rejection and UT! [24, 25]. How-
ever, despite the presence of white blood cells in urine from
patients with either rejection or infection, the precent and/or
activity of the cellular populations may differ and NO production
from one cell type can inhibit another cell type. For instance, NO
production from macrophages can inhibit lymphocyte prolifera-
tion with rat colon cancer [26].
The levels of NO oxidation-products, nitrate and nitrite, differ
significantly between renal transplant patients with rejection and
with infection. Urinary nitrate levels are significantly increased
during renal allograft rejection and urinary nitrite levels are
significantly increased in patients with urinary tract infection.
While the major source of urinary nitrate is from dietary intake,
endogenous biosynthesis of nitrate has been demonstrated in
several human studies [27—29]. One biosynthetic pathway involves
the conversion of L-arginine to NO by the enzyme nitric oxide
synthase with the subsequent oxidation of NO to nitrates [27].
Because bacteria are present with infection and bacteria convert
nitrate to nitrite, nitrite levels are elevated in patients with
infection [30, 31]. In a previous study, we found that neither
exogenous nitrate nor L-arginine increased nitrite levels in non-
infected urine, but that both increased nitrite levels in infected
urine [4].
Despite the finding that NOS activity is much higher with
infection than with rejection, cGMP levels are increased to the
same extent with both rejection and infection. Nitric oxide
activates soluble guanylyl cyclase, to stimulate the formation of
cGMP [32—34]. However, other agonists, such as atrial natriuretic
peptide, can activate particulate guanylyl cyclase [351. Therefore,
other pathways must be considered for the elevation of urinary
cGMP levels during rejection [36]. Although urinary cyclic GMP
levels are elevated in transplant rejection/infection, its actions in
this process are not known [81.
Therefore, we have identified an elevation of NOS activity with
human renal transplant rejection and demonstrated differences in
NOS activity and its products with rejection and infection in renal
transplant patients. Leukocyte iNOS in urine and the oxidation
products of NO may be early predictors of acute renal allograft
rejection or infection and the modulation of NOS activity may be
a therapeutic target [37—40]. Finding an acute increase of NO in
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Table 1. NOS activity and nitrate, nitrite and cGMP levels with renal
transplant rejection and renal transplant infection
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Fig. 5. Expression of iNOS mRNA in human urinaty cells with transplant
rejection. Using two human iNOS primers, a 413 bp iNOS and a 462 bp
iNOS, RT-PCR amplified iNOS eDNA from human liver cells (lanes 1
and 2) and amplified iNOS eDNA from urinary cells corresponding with
renal transplant rejection (lanes 3 and 4). p-actin is used as the control
amplification product (lane 5).
the cells from urine gives a source and pathway for modulating
transplant rejection.
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